When to discuss risk-reducing mastectomy in BRCA1/BRCA2 carriers after a diagnosis of advanced stage ovarian cancer can be a challenging area in providing patient-centred genetic counselling [19]. Here, BRCA2 is linked to ovarian carcinoma.